临床前放化疗联合测试联盟(PCRTC)的概况与经验总结
本文介绍美国国立癌症研究所(NCI)于2017年通过PAR 16-111征集并组建的临床前放化疗联合测试联盟(PCRTC),由4个U01项目组成,聚焦胰腺、肺、头颈、消化道和脑肿瘤,旨在生成分子靶向药物联合放化疗的高质量临床前验证数据,为优先选择NCI支持的候选药物及加速联合治疗模式进入临床实践提供依据。
要点
- PCRTC由NCI通过PAR 16-111征集,含4个U01项目。
- 聚焦胰腺、肺、头颈、消化道和脑肿瘤的放化疗联合。
- 目标是生成分子靶向药物联合放化疗的高质量临床前数据。
核心结论
- PCRTC为优先选择NCI支持的、最可能在放化疗中具有临床活性的在研新药提供合理依据。
- PCRTC旨在加速更有效的联合治疗模式被识别并纳入标准治疗实践。
- 本文介绍并总结PCRTC至今的历程,并报告联盟工作至今的3项初步观察。
研究设计与样本
- 2017年NCI通过PAR 16-111征集提案,组建临床前放化疗联合测试联盟(PCRTC)。
- PCRTC由4个U01项目组成,获资助以生成分子靶向药物联合标准治疗的高质量临床前验证数据。
- 研究重点为胰腺癌、肺癌、头颈部癌、消化道癌和脑癌。
主要发现
- PCRTC已形成并运行,用于评估分子靶向药物联合放化疗的临床前效应。
- 联盟工作至今产生3项初步观察,文中予以报告。
临床怎么用
- 可利用PCRTC生成的临床前验证数据,为NCI支持的候选药物联合放化疗的临床转化优先级提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the current molecular-targeted cancer treatment era, many new agents are being developed so that optimizing therapy with a combination of radiation and drugs is complex. The use of emerging laboratory technologies to further biological understanding of drug-radiation mechanisms of action will enhance the efficiency of the progression from preclinical studies to clinical trials. In 2017, the National Cancer Institute (NCI) solicited proposals through PAR 16-111 to conduct preclinical research combining targeted anticancer agents in the Cancer Therapy Evaluation Program's portfolio with chemoradiation. METHODS AND MATERIALS: The Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC) was formed with 4 U01 programs supported to generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies with a concentration on cancers of the pancreas, lung, head and neck, gastrointestinal tract, and brain. RESULTS: The PCRTC provides a rational basis for prioritizing NCI-supported investigational new drugs or agents most likely to have clinical activity with chemoradiotherapy and accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard treatment practices. CONCLUSIONS: Herein, we introduce and summarize the course of the PCRTC to date and report 3 preliminary observations from the consortium's work to date.
引用
- Buchsbaum JC, Coleman CN, Bernhard EJ, et al. Overview and Lessons From the Preclinical Chemoradiotherapy Testing Consortium. Int J Radiat Oncol Biol Phys. 2021. PMID: 34348172. doi:10.1016/j.ijrobp.2021.07.1709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。